Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 1678

Sort by

Sort Order Select

Journal Articles

FXII inhibition: multipronged benefits

Helen Philippou

Blood (2021) 138 (2): 107–109.

https://doi.org/10.1182/blood.2021011032

Published: 2021

Journal Articles

FV/FVa revealed

Josefin Ahnström

Blood (2021) 137 (22): 3011–3013.

https://doi.org/10.1182/blood.2021011573

Published: 2021

Journal Articles

SPARCing the clot

Bram van Os, Esther Lutgens

Blood (2021) 137 (11): 1441–1442.

https://doi.org/10.1182/blood.2020009204

Published: 2021

Journal Articles

Anticoagulant activity of edoxaban in patients with cirrhosis

Sarah Bos, Tim Schreuder, Hans Blokzijl, Jelle Adelmeijer, Ton Lisman, Pieter W. Kamphuisen

Blood (2020) 136 (13): 1561–1564.

https://doi.org/10.1182/blood.2020005319

Published: 2020

Journal Articles

Magnetic resonance imaging for diagnosis of recurrent ipsilateral deep vein thrombosis

Blood (2020) 135 (16): 1377–1385.

https://doi.org/10.1182/blood.2019004114

Published: 2020

Includes: Multimedia, Supplemental data

Journal Articles

Diagnosing HIT: the need for speed

Adam Cuker, Douglas B. Cines

Blood (2020) 135 (14): 1082–1083.

https://doi.org/10.1182/blood.2019004676

Published: 2020

Journal Articles

How I treat obese patients with oral anticoagulants

Tzu-Fei Wang, Marc Carrier

Blood (2020) 135 (12): 904–911.

https://doi.org/10.1182/blood.2019003528

Published: 2020

Journal Articles

How I assess and manage the risk of bleeding in patients treated for venous thromboembolism

Frederikus A. Klok, Menno V. Huisman

Blood (2020) 135 (10): 724–734.

https://doi.org/10.1182/blood.2019001605

Published: 2020

Journal Articles

The phase 3 pediatric anticoagulant era

Neil A. Goldenberg, Brian R. Branchford

Blood (2020) 135 (7): 459–460.

https://doi.org/10.1182/blood.2019004340

Published: 2020

Journal Articles

Managing thromboembolic risk in patients with hereditary and acquired thrombophilias

Jason Moran, Kenneth A. Bauer

Blood (2020) 135 (5): 344–350.

https://doi.org/10.1182/blood.2019000917

Published: 2020

Journal Articles

Novel antithrombotic strategies for treatment of venous thromboembolism

Jeffrey I. Weitz, Noel C. Chan

Blood (2020) 135 (5): 351–359.

https://doi.org/10.1182/blood.2019000919

Published: 2020

Journal Articles

Acute treatment of venous thromboembolism

Cecilia Becattini, Giancarlo Agnelli

Blood (2020) 135 (5): 305–316.

https://doi.org/10.1182/blood.2019001881

Published: 2020

Journal Articles

Long-term treatment of venous thromboembolism

Clive Kearon, Susan R. Kahn

Blood (2020) 135 (5): 317–325.

https://doi.org/10.1182/blood.2019002364

Published: 2020

Journal Articles

Low factor V level ameliorates bleeding diathesis in patients with combined deficiency of factor V and factor VIII

Yanyan Shao, Wenman Wu, Guanqun Xu, Xuefeng Wang, Qiulan Ding

Blood (2019) 134 (20): 1745–1754.

https://doi.org/10.1182/blood.2018886069

Published: 2019

Includes: Supplemental data

Journal Articles

Low FV beneficial in FVFVIII deficiency?

Björn Dahlbäck

Blood (2019) 134 (20): 1686–1688.

https://doi.org/10.1182/blood.2019003243

Published: 2019

Journal Articles

Predictors of Bleeding in the Perioperative Anticoagulant Use for Surgery Evaluation (PAUSE) Study

Alfonso J Tafur, MD MS, Na Li, PhD, Nathan Clark, PharmD, Sam Schulman, MD PhD FRCPC, Alex Spyropoulos, MD, Joseph A Caprini, MD MS, FACS, RVT, James Douketis, MD

Blood (2019) 134 (Supplement_1): 710.

https://doi.org/10.1182/blood-2019-125292

Published: 2019

Journal Articles

Increased Mortality and Bleeding in a Large Cohort of Patients on Heparin Anticoagulation Therapy with Discordant Anti-Factor Xa Activity and Activated Partial Thromboplastin Time (PTT); Implications for Clinical Management

Saurabh Gombar, MD PhD, Derek Boothroyd, PhD, Anandi Krishnan, PhD, Husham Sharifi, MD, Joe Hsu, MD, James Zehnder, MD

Blood (2019) 134 (Supplement_1): 712.

https://doi.org/10.1182/blood-2019-132112

Published: 2019

Journal Articles

Significant Impact of the Molecular Profile on the Prognosis of Patients with Myeloproliferative Neoplasms and Splanchnic Vein Thromboses

Pierre-Edouard Debureaux, Bruno Cassinat, PharmD, PhD, Juliette Soret-Dulphy, MD, Emmanuelle Verger, PhD, Nabih Maslah, PharmD, Pierre-Emmanuel Rautou, MD PhD, Aurelie Plessier, Dominique Valla, Stephane Giraudier, MD PhD, Jean-Jacques Kiladjian, MD PhD

Blood (2019) 134 (Supplement_1): 836.

https://doi.org/10.1182/blood-2019-123775

Published: 2019

Journal Articles

Prothrombin Complex Concentrates (PCCs) Have Limited Effect on TF-Initiated Thrombin Generation in FXa Inhibitor-Anticoagulated Plasma: In Vitro Comparison between Direct Reversal By Andexanet Alfa and "Work Around" By PCCs

Genmin Lu, Joyce P. Lin, BS, Khanh Bui, BS, John T. Curnutte, MD PhD, Pamela B. Conley, PhD

Blood (2019) 134 (Supplement_1): 713.

https://doi.org/10.1182/blood-2019-124864

Published: 2019

Journal Articles

Andexanet Alpha Differentially Neutralizes the Anticoagulant, Antiprotease and Thrombin Generation Inhibitory Effects of Unfractionated Heparin, Enoxaparin and Fondaparinux

Fakiha Siddiqui, Alfonso J Tafur, MD MS, Debra Hoppensteadt, PhD, Jeanine Walenga, PhD, Walter Jeske, PhD, Emily Bontekoe, Ahmed Kouta, Jawed Fareed, PhD

Blood (2019) 134 (Supplement_1): 1158.

https://doi.org/10.1182/blood-2019-127072

Published: 2019

NARROW

FXII inhibition: multipronged benefits

FV/FVa revealed

SPARCing the clot

Anticoagulant activity of edoxaban in patients with cirrhosis

Magnetic resonance imaging for diagnosis of recurrent ipsilateral deep vein thrombosis

Diagnosing HIT: the need for speed

How I treat obese patients with oral anticoagulants

How I assess and manage the risk of bleeding in patients treated for venous thromboembolism

The phase 3 pediatric anticoagulant era

Managing thromboembolic risk in patients with hereditary and acquired thrombophilias

Novel antithrombotic strategies for treatment of venous thromboembolism

Acute treatment of venous thromboembolism

Long-term treatment of venous thromboembolism

Low factor V level ameliorates bleeding diathesis in patients with combined deficiency of factor V and factor VIII

Low FV beneficial in FVFVIII deficiency?

Predictors of Bleeding in the Perioperative Anticoagulant Use for Surgery Evaluation (PAUSE) Study

Increased Mortality and Bleeding in a Large Cohort of Patients on Heparin Anticoagulation Therapy with Discordant Anti-Factor Xa Activity and Activated Partial Thromboplastin Time (PTT); Implications for Clinical Management

Significant Impact of the Molecular Profile on the Prognosis of Patients with Myeloproliferative Neoplasms and Splanchnic Vein Thromboses

Prothrombin Complex Concentrates (PCCs) Have Limited Effect on TF-Initiated Thrombin Generation in FXa Inhibitor-Anticoagulated Plasma: In Vitro Comparison between Direct Reversal By Andexanet Alfa and "Work Around" By PCCs

Andexanet Alpha Differentially Neutralizes the Anticoagulant, Antiprotease and Thrombin Generation Inhibitory Effects of Unfractionated Heparin, Enoxaparin and Fondaparinux

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only